Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).
about
Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners.Debate: Should the elderly receive thrombolytic therapy, or primary angioplasty, for acute myocardial infarction? The case for primary angioplastyIntracerebral haemorrhage after thrombolytic therapy for acute myocardial infarctionThe role of angioplasty in acute myocardial infarction.The treatment of myocardial infarction.An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.Medical therapy of acute myocardial infarction: Part I. Role of thrombolytic and antithrombotic therapy.Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction.Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.Management of myocardial infarction: implications for current policy derived from the Nottingham Heart Attack RegisterComparison of diagnostic accuracy, time dependency, and prognostic impact of abnormal Q waves, combined electrocardiographic criteria, and ST segment abnormalities in right ventricular infarction.Therapeutic options in treating acute myocardial infarction.The clinical challenges of myocardial infarction in the elderly.Quality of life in the first 100 days after suspected acute myocardial infarction--a suitable trial endpoint?Choosing quality of care measures based on the expected impact of improved care on health.Thrombolysis in acute myocardial infarction: the safety and efficiency of treatment in the accident and emergency department.ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative GroupThrombolytic drugs in acute myocardial infarction.Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarctionGuidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction.Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.Thrombolytic therapy for acute myocardial infarction.Management of myocardial infarction in the community: a new RCGP studyBiotechnology and clinical trials.Coronary revascularization after thrombolytic therapy for myocardial infarction: what caseloads could Canadian centres face?Coronary thrombolysis--clinical guidelines and public policy: results of an Ontario practitioner survey.Inflation of type I error rate in two statistical tests for the detection of publication bias in meta-analyses with binary outcomes.Effect of early revascularisation in cardiogenic shock complicating acute myocardial infarction. A single center experience.Intravenous thrombolysis for suspected myocardial infarction: a cautionary noteThrombolysis and the general practitioner. 2. Useful after careful evaluation of patients.Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis.Clearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implications.Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysisCardiac rehabilitation: socially deprived patients are less likely to attend but patients ineligible for thrombolysis are less likely to be invitedThrombolytic therapy is indicated for patients over 75 years of age with st-elevation acute myocardial infarction: protagonist viewpoint.Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.Current status of thrombolytic therapy in acute myocardial infarctionThe implications of a growing evidence base for drug use in elderly patients. Part 3. Beta-adrenoceptor blockers in heart failure and thrombolytics in acute myocardial infarction.
P2860
Q24536312-AC681049-B786-40ED-BAA8-8BAA5B35115EQ24792897-A71A742F-3CFD-4C39-BE90-638983AF5A54Q28317735-D6970C0E-4268-46D2-8D69-6FCD4F2511ABQ33568558-47C91BE8-2E3C-4C52-9DFD-A1ED42B3A7BFQ33571600-7789A72C-C7E2-4A49-B337-A56A3B7746CCQ33577525-C6D668CC-B310-4910-8249-6CC6D628BD9FQ33578123-7A937F44-75F0-4EF3-ABE9-3C8505C39C1CQ33610455-AAF59CD3-23C6-4BA6-BA6A-EA999B75DFBCQ33611181-FD49B4CD-E712-4185-8A93-DBD44B75A880Q33611581-536C4AA2-3D85-468B-A8AE-B4B51219348BQ33611773-BF2DC3EB-6E19-4885-8C3E-A1C39AFB6EB5Q33613957-05828C91-5991-45C4-BDDB-B7E1F0FA599FQ33617268-B3B6F099-5FBE-4C4B-B867-F8A6578F41EDQ33617341-F6C78D86-2FB3-41E3-BEF5-65BC422E90B6Q33701486-F8AFBA55-DAA8-4DAA-ABCD-69CD68CFD6B6Q33725005-923B31CC-7A1C-4C21-B462-062A1E6B4B24Q33743487-3E87CBF0-2399-4DC1-AD6F-6ED5BBFEF1FDQ33782683-A3CF44DD-D7E3-4452-9108-4AD4F0F7871AQ33868351-717C0B0C-4641-402E-9165-4FF678476481Q33955700-49262742-4166-4E91-92C3-2F5975F72E71Q34103716-CA1A2D36-5893-4E06-AA04-4360425CC8F3Q34159377-F1FEF456-0DAF-435B-A4C7-B8F0BACA6FA2Q34208881-4F0342B8-A084-43B0-A5E8-A8BB3DB1F110Q34342262-F97897A8-F48F-4E95-914C-9472E79E4218Q34368946-7C058523-D6BC-42C8-83D1-C3D2E7AA7C20Q34543904-FB8E4FDE-34B6-45EF-B7E8-5C1236453524Q34576786-0E72E23F-95EB-4B70-B23F-2B82EF95AC97Q34578045-5AC50047-ACD8-4A68-B4AF-0D1FEE81FE7CQ34805880-47A1E00C-0DA4-4594-9EB5-5D5B7362A86BQ35057078-3256558A-CE04-4214-8FE2-2B6C578078CFQ35168064-9C041F6B-D8E1-48C1-BD2D-DC3957FDA272Q35168511-AA1D126F-14E6-4A31-BA7A-0B191778AF2DQ35188741-0C3E2FD2-0E06-4B19-9C36-525977EE38DFQ35224553-40EFEC2D-6028-4815-A401-4B2F04565A88Q35372488-F7AD38B5-5C8D-45A2-8A99-4631A75954B1Q35373548-EE874DAD-85C9-4659-AC05-2598E7664968Q35580939-33CED2AC-6AC9-4592-AF5C-4C25F63977E8Q35655575-A6671E74-DC69-4DDA-B028-A1BE7C00A2DFQ35687099-0881FEB5-0BF5-400D-B924-676FFC2BCB46Q35827573-8CAFE7CD-21B4-425F-8195-521C4B86F076
P2860
Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Trial of tissue plasminogen ac ...... of Early Thrombolysis (ASSET).
@en
Trial of tissue plasminogen ac ...... an Study of Early Thrombolysis
@nl
type
label
Trial of tissue plasminogen ac ...... of Early Thrombolysis (ASSET).
@en
Trial of tissue plasminogen ac ...... an Study of Early Thrombolysis
@nl
prefLabel
Trial of tissue plasminogen ac ...... of Early Thrombolysis (ASSET).
@en
Trial of tissue plasminogen ac ...... an Study of Early Thrombolysis
@nl
P2093
P1433
P1476
Trial of tissue plasminogen ac ...... of Early Thrombolysis (ASSET).
@en
P2093
C G Olsson
G von der Lippe
J R Hampton
R G Wilcox
P304
P356
10.1016/S0140-6736(88)92656-6
P407
P577
1988-09-01T00:00:00Z